C. Avendaño
206
organo-‐tellurium compound AS101 against
Enterobacter cloacae
”;
J. Antimicrob.
Chemother
., 67, 2165-‐2172.
12.
Indenbaum, V.; Bin, H.; Makarovsky, D.; Weil, M.; Shulman, L. M.; Albeck, M.; Sredni, B.;
Mendelson, E.; (2012) “In vitro and in vivo activity of AS101 against West Nile virus
(WNV)”;
Virus Res.
, 166, 68-‐76.
13.
Sredni-‐Kenigsbuch, D.; Sota, M.; Shohat, B.; Ben-‐Amitai, D.; Chan, C. C.; David, M.; (2008)
“The novel tellurium immunomodulator AS101 inhibits interleukin-‐10 production and
p38 MAPK expression in atopic dermatitis”;
J. Dermatol. Sci
.; 50, 232-‐235.
14.
Sredni, B.; Gal, R.; Cohen, I. J.; Dazard, J. E.; Givol, D.; Gafter, U.; Motro, B.; Eliyahu, S.;
Albeck, M.; Lander, H. M.; Kalechman, Y.; (2004) “Hair growth induction by the Tellurium
immunomodulator AS101: association with delayed terminal differentiation of follicular
keratinocytes and ras-‐dependen up-‐regulation of KGF expression”;
FASEB J.,
18, 400-‐402.
15.
(a) Sredni, B.; Albeck, M.; Tichler, T.; Shani, A.; Shapira, J.; Bruderman, I.; Catane, R.;
Kaufman, B.; Kalechman, Y.; (1995) “Bone marrow-‐sparing and prevention of alopecia by
AS101 in non-‐small-‐cell lung cancer patients treated
with carboplatin and etoposide”,
J.
Clin. Oncol
., 13, 2342-‐2353. (b) Sredni, B.; Xu, R. H.; Albeck, M.; Gafter, U.; Gal, R.; Shani, A.;
Tichler, T.; Shapira, J.; Bruderman, I.; Catane, R.; Kaufman, B.; Whisnant, J. K.; Mettinger, K.
L.; Kalechman, Y.; (1996) “The protective role of the immunomodulator AS101 against
chemotherapy-‐induced alopecia: studies on human and animal models”,
Int. J. Cancer.
65,
97-‐103.
16.
(a) Makarovsky, D.; Kalechman, Y.; Sonino, T.; Freidkin, I.; Teitz, S.; Albeck, M.; Weil, M.;
Geffen-‐Aricha, R.; Yadid, G.; Sredni, B.; (2003) “Tellurium compound AS101 induces PC12
differentiation and rescues the neurons from apoptotic death”,
Ann. N. Y. Acad. Sci
., 1010,
659-‐666. (b) Sredni, B.; Geffen-‐Aricha; R.; Duan, W. Z.; Albeck, M.; Shalit, F.; Lander, H. M.;
Kinor, N.; Sagi, O.; Albeck, A.; Yosef, S.; Brodsky, M.; Sredni-‐Kenigsbuch, D.; Sonino, T.;
Longo, D. L.; Mattson, M. P.; Yadid, G.; (2007) “Multifunctional tellurium molecule protects
and restores dopaminergic neurons in Parkinson's disease models”;
FASEB J
., 21, 1870-‐
1883.
17.
Halperin
-‐
Sheinfeld, M., Gertler, A.; Okun, E.; Sredni, B.; Cohen, H. Y.; (2012) “The Tellurium
compound, AS101, increases SIRT1 level and activity and prevents type 2 diabetes”;
Aging
, 4, 436-‐447.
AGING, June 2012, Vol. 4, No 6
18.
Kalechman, Y.; Shani, A.; Sotnik-‐Barkai, I.; Albeck, M.; Sredni, B.; (1993) “The protective
role of ammonium trichloro(dioxoethylene-‐
O,O'
)tellurate in combination with several
cytotoxic drugs acting by different mechanisms of action”,
Cancer Res.
, 53, 5962-‐5969.
19.
Hayun, M; Naor, Y.; Weil, M.; Albeck, M.; Peled, A.; Don, J.; Haran-‐Ghera, N.; Sredni, B.;
(2006) “The immunomodulator AS101 induces growth arrest and apoptosis in multiple
myeloma: association with the Akt/survivin pathway”;
Biochem. Pharmacol
., 72, 1423-‐
1431.
